202 related articles for article (PubMed ID: 18316571)
1. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma.
Liau SS; Whang E
Clin Cancer Res; 2008 Mar; 14(5):1470-7. PubMed ID: 18316571
[TBL] [Abstract][Full Text] [Related]
2. Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma.
Liau SS; Ashley SW; Whang EE
J Gastrointest Surg; 2006 Nov; 10(9):1254-62; discussion 1263. PubMed ID: 17114012
[TBL] [Abstract][Full Text] [Related]
3. High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma.
Liau SS; Rocha F; Matros E; Redston M; Whang E
Cancer; 2008 Jul; 113(2):302-14. PubMed ID: 18473350
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of HMGA1 promotes anoikis resistance and constitutive Akt activation in pancreatic adenocarcinoma cells.
Liau SS; Jazag A; Ito K; Whang EE
Br J Cancer; 2007 Mar; 96(6):993-1000. PubMed ID: 17342093
[TBL] [Abstract][Full Text] [Related]
5. Silencing of high mobility group A1 enhances gemcitabine chemosensitivity of lung adenocarcinoma cells.
Cao YD; Huang PL; Sun XC; Ma J; Jin ZL; Cheng HY; Xu RZ; Li F; Qin SK; Deng YX; Ge XL
Chin Med J (Engl); 2011 Apr; 124(7):1061-8. PubMed ID: 21542969
[TBL] [Abstract][Full Text] [Related]
6. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
[TBL] [Abstract][Full Text] [Related]
7. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
[TBL] [Abstract][Full Text] [Related]
8. Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma.
Simon PO; McDunn JE; Kashiwagi H; Chang K; Goedegebuure PS; Hotchkiss RS; Hawkins WG
Int J Cancer; 2009 Aug; 125(4):942-51. PubMed ID: 19405118
[TBL] [Abstract][Full Text] [Related]
9. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
[TBL] [Abstract][Full Text] [Related]
10. RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance.
Duxbury MS; Ito H; Benoit E; Waseem T; Ashley SW; Whang EE
Clin Cancer Res; 2005 May; 11(9):3433-8. PubMed ID: 15867245
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D
Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
[TBL] [Abstract][Full Text] [Related]
13. BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling.
Liu X; Tian X; Wang F; Ma Y; Kornmann M; Yang Y
Eur J Cancer; 2014 Sep; 50(13):2251-62. PubMed ID: 24953335
[TBL] [Abstract][Full Text] [Related]
14. HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma.
Liau SS; Jazag A; Whang EE
Cancer Res; 2006 Dec; 66(24):11613-22. PubMed ID: 17178855
[TBL] [Abstract][Full Text] [Related]
15. siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
J Am Coll Surg; 2004 Jun; 198(6):953-9. PubMed ID: 15194078
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106
[TBL] [Abstract][Full Text] [Related]
17. A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells.
Duxbury MS; Ito H; Benoit E; Waseem T; Ashley SW; Whang EE
Cancer Res; 2004 Jun; 64(11):3987-93. PubMed ID: 15173012
[TBL] [Abstract][Full Text] [Related]
18. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
19. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y
Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607
[TBL] [Abstract][Full Text] [Related]
20. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Oncogene; 2004 Feb; 23(8):1539-48. PubMed ID: 14661056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
